Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Just three days after being diagnosed with acute myeloid leukaemia (AML), the wife of Sky Sports presenter Simon Thomas tragically died. Gemma Thomas was one of more than 3,000 people diagnosed with AML in the UK in the last year.

AML is the commonest aggressive adult human blood cancer. Despite advances in our understanding of the disease, we need to do more research to increase the number of patients who are cured.

Read the full article on The Conversation website, written by Connor Sweeney and Catherine Garnett, Radcliffe Department of Medicine.

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

National consortium to study threats of new SARS-CoV-2 variants

Coronavirus COVID-19 General Research

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Immunology preprint reviews launched in Nature Reviews Immunology

General Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.